Match!
Myrlene A. Staten
National Institutes of Health
54Publications
24H-index
3,462Citations
Publications 54
Newest
#1Erin S. LeBlancH-Index: 15
#2Richard E. PratleyH-Index: 64
Last.Anastassios G. PittasH-Index: 41
view all 26 authors...
In the article cited above, there were some differences in means and proportions of a few variables between the published data and …
Source
Abstract Background Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the...
15 CitationsSource
#1Vanita R. Aroda (MedStar Health)H-Index: 14
#2Patricia R. Sheehan (Tufts Medical Center)H-Index: 6
Last.Anastassios G. Pittas (Tufts Medical Center)H-Index: 41
view all 12 authors...
AimsTo establish recruitment approaches that leverage electronic health records in multicenter prediabetes/diabetes clinical trials and compare recruitment outcomes between electronic health record...
Source
#1Ranee Chatterjee (Durham University)H-Index: 16
#2John K. Erban (Tufts Medical Center)H-Index: 29
Last.Anastassios G. Pittas (Tufts Medical Center)H-Index: 41
view all 8 authors...
Abstract Evidence on biological plausibility from mechanistic studies and data from observational studies suggest that vitamin D may be linked to risk of several types of cancer. However, evidence from clinical trials evaluating the effect of vitamin D supplementation on cancer risk is limited. The Vitamin D and Type 2 Diabetes (D2d) study is a multi-center, randomized, placebo-controlled clinical trial conducted to examine the causal relationship between oral vitamin D supplementation and devel...
Source
#1Olivia Lovegreen (Tufts Medical Center)
#2Danielle Riggs (Tufts Medical Center)
Last.Anastassios G. Pittas (Tufts Medical Center)H-Index: 41
view all 5 authors...
Background Randomized clinical trials that have public health implications but no or low potential for commercial gain are predominantly funded by governmental (e.g., National Institutes of Health (NIH)) and not-for-profit organizations. Our objective was to develop an alternative clinical trial site funding model for judicious allocation of declining public research funds.
Source
#1Erin LeBlanc (KP: Kaiser Permanente)H-Index: 20
#2Richard E. PratleyH-Index: 64
Last.Anastassios G. Pittas (Tufts University)H-Index: 41
view all 26 authors...
OBJECTIVE To describe baseline characteristics of the Vitamin D and Type 2 Diabetes (D2d) study, the first large U.S. diabetes prevention clinical trial to apply current American Diabetes Association (ADA) criteria for prediabetes. RESEARCH DESIGN AND METHODS This is a multicenter ( n = 22 sites), randomized, double-blind, placebo-controlled, primary prevention clinical trial testing effects of oral daily 4,000 IU cholecalciferol (D 3 ) compared with placebo on incident diabetes in U.S. adults a...
5 CitationsSource
#1Sudha S. Shankar (Eli Lilly and Company)H-Index: 14
#2Douglas S. Lee (Pfizer)H-Index: 4
Last.David A. FryburgH-Index: 13
view all 13 authors...
Abstract Standard practice to minimize variability in beta cell function (BCF) measurement is to test in inpatient (IP) settings. IP testing strains trial subjects, investigators, and budgets. Outpatient (OP) testing may be a solution although there are few reports on OP BCF testing variability. We compared variability metrics between OP and IP from a standardized mixed meal tolerance test (MMTT) and arginine stimulation test (AST) in two separate type 2 diabetes (T2DM) cohorts (OP, n = 20; IP n...
Source
#1Jonathan Q. Purnell (OHSU: Oregon Health & Science University)H-Index: 36
#2Geoffrey S. Johnson (University of Pittsburgh)H-Index: 4
Last.Bruce M. Wolfe (OHSU: Oregon Health & Science University)H-Index: 55
view all 16 authors...
Aims/hypothesis In this prospective case–control study we tested the hypothesis that, while long-term improvements in insulin sensitivity (SI) accompanying weight loss after Roux-en-Y gastric bypass (RYGB) would be similar in obese individuals with and without type 2 diabetes mellitus, stimulated-islet-cell insulin responses would differ, increasing (recovering) in those with diabetes but decreasing in those without. We investigated whether these changes would occur in conjunction with favourabl...
5 CitationsSource
#1Erin LeBlanc (Stanford University)H-Index: 20
#2Richard E. Pratley (Stanford University)
Last.Anastassios G. Pittas (Stanford University)H-Index: 41
view all 12 authors...
Objective: Describe baseline characteristics of the NIH/ADA-supported D2d study, the first diabetes prevention trial in the U.S. to apply current ADA diagnostic glycemia criteria. Research Design and Methods: Multicenter (22 sites), randomized, double-blind, placebo-controlled, primary prevention trial testing efficacy of oral daily 4000 IU cholecalciferol (D 3 ) compared to placebo on incident diabetes in adults at high risk. Eligible participants met at least 2-of-3 2010 ADA glycemic criteria ...
Source
#1Michael R. Lewis (UVM: University of Vermont)H-Index: 12
#2Patricia R. Sheehan (Tufts Medical Center)H-Index: 6
Last.Anastassios G. Pittas (Tufts Medical Center)H-Index: 41
view all 5 authors...
We thank Drs. Little and Rohlfing for their comments (1) regarding our article on the management of incidental detection of hemoglobin (Hb) variants in HbA1c testing (2). We agree that awareness of the potential for interference to affect HbA1c results is essential in research and clinical care. Multiple studies (including that of Lin et al. [3]) prior to the 2016 article by Rohlfing et al. (4) had yielded no evidence of clinically significant bias resulting from HbAS or HbAC variants in Tosoh G...
Source
123456